DOCSLIB.ORG

Antenatal Dexamethasone Vs. Betamethasone Dosing for Lung Maturation in Fetal Sheep

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antenatal Dexamethasone Vs. Betamethasone Dosing for Lung Maturation in Fetal Sheep nature publishing group Articles Translational Investigation Antenatal dexamethasone vs. betamethasone dosing for lung maturation in fetal sheep Augusto F. Schmidt1, Matthew W. Kemp2, Paranthaman S. Kannan1, Boris W. Kramer3, John P. Newnham2, Suhas G. Kallapur1 and Alan H. Jobe1 BACKGROUND: Dexamethasone-phosphate (Dex-PO4) and glucocorticoid usually given in four doses of 6 mg each, 12 h the combination betamethasone-phosphate (Beta-PO4) + apart, for a total dose of 24 mg, but other dosing regimens betamethasone-acetate (Beta-Ac) are the most used antena- are also frequently used such as two doses of 12 mg, 24 h tal corticosteroids to promote fetal lung maturation. We com- apart. Betamethasone is usually given as a combination of pared fetal lung maturation induced by Beta-Ac+Beta-PO , 4 equal parts betamethasone phosphate (Beta-PO4) and beta- Dex-PO4, or Beta-PO4 alone. methasone acetate (Beta-Ac) in two doses 24 h apart of 12 mg METHODS: Pregnant ewes received two intramuscular doses each for a total dose of 24 mg. Beta-PO4 has a short biological 24h apart of 0.25mg/kg/dose of Beta-Ac+Beta-PO , Dex-PO4 or 4 half-life, similar to Dex-PO4, while Beta-Ac is a slow-release Beta-PO4; or 2 doses of 0.125 mg/kg/dose of Beta-PO4 at 6, 12, suspension with a longer half-life (3,4). In clinical practice, or 24h intervals. Fetuses were delivered 48h after the first dose different formulations, such as Beta-PO4 alone, and dosing and ventilated for 30 min. We assessed ventilatory variables, vital intervals are used despite limited data from animal or human signs, and blood gas. After ventilation pressure-volume curves studies (1,4). were measured and lungs were sampled for analysis. A meta-analysis of the clinical trials comparing dexametha- RESULTS: All treatments improved lung compliance and sone to betamethasone showed no difference in respiratory ventilation efficiency. Only Beta-Ac + Beta-PO4 required lower distress syndrome or neonatal mortality, but a decreased inci- positive inspiratory pressure compared with control. Beta-Ac + dence of intraventricular hemorrhage (IVH) with Dex-PO4, Beta-PO4 and Beta-PO4 alone, but not Dex-PO4, increased the mostly influenced by the trial from Elimian et al. (4,5). Subtil mRNA of surfactant proteins compared with control. Low-dose et al. compared the combination of Beta-PO4 + Beta-Ac to Beta-PO did not increase mRNA of surfactant proteins. There 4 Beta-PO4 alone in 69 infants and observed no difference in the were no differences among Beta-PO4 treatment intervals. outcomes of neonatal death, respiratory distress syndrome, or CONCLUSION: Beta-Ac + Beta-PO4 given as two doses 24 h IVH (6). A large randomized controlled trial of betamethasone apart was more effective in promoting fetal lung maturation combination drug vs. dexamethasone using a 2 dose 12 mg and than Dex-PO4 or Beta-PO4 alone, consistent with a prolonged 24-h treatment interval with long term follow up is currently exposure provided by the Beta-Ac + Beta-PO4. These results underway in Australia (7). support the clinical use of combined Beta-Ac + Beta-PO prep- 4 A recent trial of antenatal corticosteroids using Dex-PO4 arations over phosphate corticosteroids alone for fetal lung in low resource environments including almost 100,000 live- maturation. births found no benefit for small infants but increased mor- tality for large infants exposed to prenatal Dex-PO4 (8). The ability to distinguish between treatment responses to different ntenatal corticosteroids decrease the incidence of respira- corticosteroids, doses, and treatment intervals is impractical Atory distress syndrome and other neonatal morbidities in given the number of variables and large number of patients preterm infants and are considered standard of care for women needed for multiple trials. The sheep model of preterm birth at risk of preterm delivery (1). Despite widespread clinical use and lung maturation allows the analysis of gas exchange and there is minimal experimental evidence regarding the formu- ventilatory variables in a stage of lung development similar to lation or dosing regimen, thus multiple different treatments preterm newborns (9). To provide guidance about maturation are used worldwide (2). responses we compared the fetal lung maturation from clini- Dexamethasone and betamethasone are the fluorinated cally used doses of antenatal Beta-PO4+Beta-Ac to Dex-PO4 or steroids most commonly used for maternal treatment (2). Beta-PO4 alone, as well as a lower dose of Beta-PO4 alone with Dexamethasone phosphate (Dex-PO4) is a short acting different dosing intervals, in preterm sheep. 1Division of Neonatology and Pulmonary Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 2School Women’s and Infants’ Health, University of Western Australia, Perth, Australia; 3Department of Pediatrics, University of Maastricht, Maastricht, Netherlands. Correspondence: Alan H. Jobe ([email protected]) Received 16 May 2016; accepted 26 September 2016; advance online publication 11 January 2017. doi:10.1038/pr.2016.249 496 Pediatric REsEarcH Volume 81 | Number 3 | March 2017 Copyright © 2017 International Pediatric Research Foundation, Inc. Steroid formulation for lung maturation Articles METHODS compliance was recorded as measured by the ventilator. The ventila- Antenatal Corticosteroid Treatments tion efficiency index (VEI) was calculated using the formula VEI = The animal ethics committee of The University of Western Australia 3,800/(respiratory rate (PIP − PEEP) × PCo2 (mm Hg)). approved the animal studies (RA/3/100/1378). All animals received Lung Assessment an i.m. injection of 150 mg medroxyprogesterone acetate (Depo- After ventilation for 30 min lambs were disconnected from the ven- Provera, Pfizer, New York, NY) at 115 ± 1 d gestation to decrease the tilator and the endotracheal tube was clamped for 2 min to achieve risk of steroid-induced premature labor. Time-mated Merino ewes atelectasis by oxygen absorption. The lambs received a lethal dose with singleton fetuses received maternal i.m. injections based on of pentobarbital, were weighed and the chest was opened for visual maternal weight of normal saline or corticosteroid treatments with evaluation of gross lung injury–pulmonary hemorrhage, pulmonary the first dose given on 120 ± 1 d of gestation (80% of gestation, term interstitial emphysema, gas pockets within the lung or subpleural = 150 d). A composite group of control ewes received two doses of dissection—performed by the same investigator. A deflation pres- normal saline i.m. 6, 12, or 24 h apart. Treatment groups received: two sure-volume curve was measured after air inflation of the lungs to a doses of Beta-PO4+Beta-Ac (Celestone Chronodose, Merck Sharp pressure of 40 cmH O (8). & Dohme, Australia) 0.25 mg/kg/dose i.m. 24 h apart; two doses of 2 Quantitation of mRNA Dex-PO4 (DBL Dexamethasone sodium phosphate, Hospira NZ, Total RNA was isolated from frozen lungs after homogenization with New Zealand) 0.25 mg/kg/dose i.m. 24 h apart; two doses of Beta-PO4 (Betnesol, Focus Pharmaceuticals, UK) 0.25 mg/kg/dose i.m. 24 h TRIzol (Invitrogen, Carlsbad, CA). Reverse transcription was per- formed using Verso cDNA kit (Thermo Scientific, Waltham, MA) apart. Other groups received two doses of Beta-PO4 0.125 mg/kg/dose i.m. 6, 12, or 24 h apart. We adopted the standard dose of 0.25 mg/kg/ to produce single-strand cDNA. The genes for surfactant protein A (SPA), surfactant protein B (SPB), surfactant protein C (SPC), sur- dose of Beta-PO4 + Beta-Ac to maintain dosing regimens comparable with previous studies from our group. All animals were delivered 48 h factant protein D (SPD), ATP-binding cassette subfamily A member after the first i.m. injection at 122 ± 1 d of gestation. 3 (ABCA3)——expressed by type 2 alveolar cells, and aquaporin 5 (AQP5)—expressed by type 1 alveolar cells, were amplified using Ventilatory Assessment the cDNA template and sheep-specific primers along with Taqman For delivery pregnant ewes received i.v. midazolam (0.5 mg/kg) probes (Applied Biosystems, Foster City, CA). The mRNA expression and ketamine (10 mg/kg) for sedation. Then, 3 ml of 2% (20 mg/ml) for each gene was normalized to the mRNA for the ribosomal protein lidocaine was given for spinal anesthesia for delivery of the fetus. 18s as internal standard. Final data are expressed as fold increase over The head of the fetus was delivered through abdominal and uterine the control value. incisions and the fetal skin over the trachea was infiltrated with lido- caine. A 4 mm endotracheal tube was secured by tracheostomy. After Statistical Analysis delivery of the fetus the ewe was killed with pentobarbital. The lamb Data are presented as mean ± SEM. Statistical tests were performed was weighed and dried, and temperature maintained with a radiant with Prism software 6.0 (GraphPad Software, San Diego, CA). Initial warmer (Cozy Cot, Fisher & Paykel Healthcare, New Zealand) and comparisons were performed with ANOVA followed by multiple a plastic cover (Neowrap, Fisher & Paykel, NZ). Mechanical venti- groups comparison with Tukey’s post-hoc test, with separate ANOVA lation (Fabian HFO, Accutronic Medical Systems AG, Switzerland) tests performed for the comparison among Beta-PO4 + Beta-Ac, was immediately started with the following settings: peak inspira- Dex-PO4, and Beta-PO4 alone, among Beta-PO4 + Beta-Ac, standard and low dose Beta-PO , and among the low-dose Beta-PO intervals. tory pressure (PIP) of 40 cmH2O, positive end expiratory pressure 4 4 Selected group comparisons were performed by t-tests where appro- (PEEP) of 5 cmH2O, respiratory rate of 50 breaths per minute, inspi- ratory time of 0.6 s, and 100% heated and humidified oxygen. The priate and are indicated in the results section. Significance was attrib- standard use of 100% oxygen allows the comparison of oxygenation uted for P-values < 0.05.
Load more

Recommended publications
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • Product Portfolio
    API Product Portfolio Hovione has developed a range of particle engineered Particle Engineered APIs APIs with superior powder properties that will address the challenges of your formulation development. Corticosteroids PRODUCT ROUTE OF CAS CUSTOMIZED REGULATORY ADMINISTRATION NUMBER PARTICLE SIZE STATUS Beclomethasone Dipropionate Anhydrous Inhalation Nasal Oral Topical 5534-09-08 Beclomethasone Dipropionate Monohydrate Inhalation Nasal 77011-63-3 US DMF Betamethasone Acetate Ophtalmic Injectable 987-24-6 US DMF Betamethasone Disodium Phosphate Ophtalmic Injectable Topical 151-73-5 US DMF, JP DMF Fluticasone Furoate Inhalation Nasal 397864-44-7 US DMF CEP, US DMF, JP DMF, Fluticasone Propionate Inhalation Nasal Topical 80474-14-2 CN DMF Halobetasol Propionate Topical 66852-54-8 US DMF Hydrocortisone Aceponate Topical 74050-20-7 ASMF & VMF Mometasone Furoate Anhydrous Inhalation Nasal Topical 83919-23-7 CEP, US DMF, JP DMF Mometasone Furoate Monohydrate Inhalation Nasal 141646-00-6 CEP, US DMF, JP DMF LABA/LAMA PRODUCT ROUTE OF CAS CUSTOMIZED REGULATORY ADMINISTRATION NUMBER PARTICLE SIZE STATUS Aclidinium Bromide Inhalation 320345-99-1 US DMF Glycopyrronium Bromide Inhalation 51186-83-5 US DMF Salmeterol Xinafoate Inhalation 94749-08-3 CEP, US DMF Indacaterol Maleate Inhalation 312753-06-3 DEV Olodaterol Sulphate Inhalation 869477-96-3 DEV Salbutamol Inhalation 18559-94-9 GMP, TECH PACK Tiotropium Bromide Monohydrate Inhalation 136310-93-5 DEV Umeclidinium Bromide Inhalation 869113-09-7 DEV, TECH PACK Vilanterol Trifenatate Inhalation 503070-58-4 GMP, TECH PACK Hovione provides the peace of mind of a high quality Security of supply manufacturer who is a founding member of Rx-360 and has an unblemished regulatory track record.
    [Show full text]
  • Product List
    Arena Product List A Cabazitaxel (Under Development) Acebutolol HCl Calcitriol N-Acetyl-L-Asparagine Calcifediol N-Acetyl-L-Aspartic Acid Calcipotriol Monohydrate Acexamic Acid (Upon Request) Canrenoate K Aesculin Canrenone micronised Agomelatine (Under Development) Capecitabine Alfacalcidol Captopril Alimemazine Tartrate Carbamizole Aliskiren Fumarate (Under Development) Carbasalate Calcium Altizide Carbomers Amcinonide Acetyl Thiazolidin Carboxylic Acid Amifostine L-Carnitine Base Amiodarone HCl (Upon Request) Acetyl-L-Carnitine HCl Amisulpride (Upon Request) Acetyl Carnosine Amitriptyline HCl L-Carnosine Apomorphine HCl Cefaclor L-Arginine Base Cefalexin Monohydrate L-Arginine-L-Aspartate Cefamandole Nafate Sterile L-Arginine-L-Glutamate Cefazedone Sodium Sterile Aripiprazole (Under Development) Cefepime HCL Artesunate (Upon Request) Cefmetazole Artemether (Upon Request) Cefmetazole Sodium Sterile Articaine HCl Cefminox Sodium Sterile L-Asparagine Anyhdrous Cefodizime Disodium L-Asparagine Monohydrate Cefodizime Sodium Sterile DL-Aspartic Acid Magnesium Salt Cefotetan DL-Aspartic Acid Magnesium + Potassium Salt Cefotetan Sodium Sterile DL-Aspartic Acid Potassium Salt Cefozopran (Under Development) L-Aspartic Acid Sodium Salt Monohydrate Cefsulodin (Under Development) Atovaquone (Under Development) Cefsulodin Sodium Sterile Azacitidine (Under Development) Cefuroxime Sodium Azathioprine Powder Cefuroxime Sodium Sterile Centella Asiatica Extract B Cephacetrile Sodium Sterile Baclofen Cetirizine HCl Beclomethasone Base Cetrimide Powder
    [Show full text]
  • Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids
    Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. K B Horwitz, L D Horwitz J Clin Invest. 1982;69(4):750-758. https://doi.org/10.1172/JCI110513. Research Article Sex differences and steroid hormones are known to influence the vascular system as shown by the different incidence of atherosclerosis in men and premenopausal women, or by the increased risk of cardiovascular diseases in women taking birth control pills or men taking estrogens. However, the mechanisms for these effects in vascular tissues are not known. Since steroid actions in target tissues are mediated by receptors, we have looked for cytoplasmic steroid receptor proteins in vascular tissues of dogs. We find specific saturable receptors, sedimenting at 8S on sucrose density gradients for estrogens (measured with [3H]estradiol +/- unlabeled diethylstilbestrol), androgens (measured with [3H]R1881 +/- unlabeled R1881 and triamcinolone acetonide), and glucocorticoids (measured with [3H]dexamethasone +/- unlabeled dexamethasone); they are absent for progesterone (measured with [3H]R5020 +/- unlabeled R5020 and dihydrotestosterone). Progesterone receptors can, however, be induced by 1-wk treatment of dogs with physiological estradiol concentrations (100 pg/ml serum estrogen), indicating a functional estrogen receptor. Receptor levels range from 20 to 2,000 fmol/mg DNA. They are specific for each hormone; unrelated steroids fail to complete for binding. Low dissociation constants, measured by Scatchard analyses, show that binding is of high affinity. Steroid binding sites are in the media and/or adventitia since they persist when the intima is removed. Compared with the arteries, receptor levels are reduced 80% in inferior venae cavae of […] Find the latest version: https://jci.me/110513/pdf Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids KATHRYN B.
    [Show full text]
  • Dexamethasone Inhibits the Induction of NAD+-Dependent 15
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1497 (2000) 61^68 www.elsevier.com/locate/bba Dexamethasone inhibits the induction of NAD-dependent 15-hydroxyprostaglandin dehydrogenase by phorbol ester in human promonocytic U937 cells Min Tong 1, Hsin-Hsiung Tai * Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082, USA Received 29 December 1999; received in revised form 2 March 2000; accepted 9 March 2000 Abstract Pro-inflammatory prostaglandins are known to be first catabolized by NAD-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) to inactive metabolites. This enzyme is under regulatory control by various inflammation-related agents. Regulation of this enzyme was investigated in human promonocytic U937 cells. 15-PGDH activity was found to be optimally induced by phorbol 12-myristate 13-acetate (PMA) at 10 nM after 24 h of treatment. The induction was blocked by staurosporine or GF 109203X indicating that the induction was mediated by protein kinase C. The induction by PMA was inhibited by the concurrent addition of dexamethasone. Nearly complete inhibition was observed at 50 nM. Other glucocorticoids, such as hydrocortisone and corticosterone, but not sex hormones, were also inhibitory. Inhibition by dexamethasone could be reversed by the concurrent addition of antagonist mifepristone (RU-486) indicating that the inhibition was a receptor-mediated event. Either induction by PMA or inhibition by dexamethasone the 15-PGDH activity correlated well with the enzyme protein expression as shown by the Western blot analysis. These results provide the first evidence that prostaglandin catabolism is regulated by glucocorticoids at the therapeutic level.
    [Show full text]
  • Dexamethasone in Patients with Acute Lung Injury from Acute Monocytic Leukaemia
    Eur Respir J 2012; 39: 648–653 DOI: 10.1183/09031936.00057711 CopyrightßERS 2012 Dexamethasone in patients with acute lung injury from acute monocytic leukaemia E´. Azoulay*, E. Canet*, E. Raffoux#, E. Lengline´#, V. Lemiale*, F. Vincent*, A. de Labarthe#, A. Seguin*, N. Boissel#, H. Dombret# and B. Schlemmer* ABSTRACT: The use of steroids is not required in myeloid malignancies and remains AFFILIATIONS controversial in patients with acute lung injury (ALI) or acute respiratory distress syndrome *Medical ICU and #Hematology Dept, Saint-Louis (ARDS). We sought to evaluate dexamethasone in patients with ALI/ARDS caused by acute Hospital, Paris, France. monocytic leukaemia (AML FAB-M5) via either leukostasis or leukaemic infiltration. Dexamethasone (10 mg every 6 h until neutropenia) was added to chemotherapy and intensive CORRESPONDENCE ´ care unit (ICU) management in 20 consecutive patients between 2005 and 2008, whose data were E. Azoulay AP-HP compared with those from 20 historical controls (1994–2002). ICU mortality was the primary Hoˆpital Saint-Louis criterion. We also compared respiratory deterioration rates, need for ventilation and nosocomial Medical ICU infections. 75010 Paris 17 (85%) patients had hyperleukocytosis, 19 (95%) had leukaemic masses, and all 20 had France E-mail: [email protected] severe pancytopenia. All patients presented with respiratory symptoms and pulmonary infiltrates paris.fr prior to AML FAB-M5 diagnosis. Compared with historical controls, dexamethasone-treated patients had a significantly lower ICU mortality rate (20% versus 50%; p50.04) and a trend for less Received: respiratory deterioration (50% versus 80%; p50.07). There were no significant increases in the May 24 2011 Accepted after revision: rates of infections with dexamethasone.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • WO 2013/066179 Al 10 May 2013 (10.05.2013) W P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/066179 Al 10 May 2013 (10.05.2013) W P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/127 (2006.01) A61P 29/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/NL20 12/050766 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 November 2012 (02.1 1.2012) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PCT/NL201 1/050755 (84) Designated States (unless otherwise indicated, for every 4 November 20 11 (04. 11.20 11) NL kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: ENCELADUS PHARMACEUTICALS B.V.
    [Show full text]
  • Corticosteroids in Terminal Cancer-A Prospective Analysis of Current Practice
    Postgraduate Medical Journal (November 1983) 59, 702-706 Postgrad Med J: first published as 10.1136/pgmj.59.697.702 on 1 November 1983. Downloaded from Corticosteroids in terminal cancer-a prospective analysis of current practice G. W. HANKS* T. TRUEMAN B.Sc., M.B., B.S., M.R.C.P.(U.K.) S.R.N. R. G. TWYCROSS M.A., D.M., F.R.C.P. Sir Michael Sobell House, The Churchill Hospital, Headington, Oxford OX3 7LJ Summary Introduction Over half of a group of 373 inpatients with advanced Corticosteroids have a major role to play in the malignant disease were treated with corticosteroids control of symptoms in patients with advanced for a variety of reasons. They received either pred- malignant disease. They may be employed in a non- nisolone or dexamethasone, or replacement therapy specific way to improve mood and appetite; or they with cortisone acetate. Forty percent of those receiv- may be indicated as specific adjunctive therapy in the ing corticosteroids benefited from them. A higher relief of symptoms related to a large tumour mass or response rate was seen when corticosteroids were to nerve compression. The management of a numberProtected by copyright. prescribed for nerve compression pain, for raised of other symptoms and syndromes may also be intracranial pressure, and when used in conjunction facilitated by treatment with corticosteroids (Table with chemotherapy. No significant difference in 1). efficacy was noted between the 2 drugs. The results, The use of corticosteroids in patients with ad- however, suggest that with a larger sample, dexame- vanced cancer is empirical, as it is in other non- thasone would have been shown to be significantly endocrine indications.
    [Show full text]
  • Dexamethasone and Fludrocortisone Inhibit Hedgehog Signaling In
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Article Cite This: ACS Omega 2018, 3, 12019−12025 http://pubs.acs.org/journal/acsodf Dexamethasone and Fludrocortisone Inhibit Hedgehog Signaling in Embryonic Cells † ‡ † ‡ Kirti Kandhwal Chahal,*, , Milind Parle, and Ruben Abagyan*, † Department of Pharmaceutical Sciences, G. J. University of Science and Technology, Hisar 125001, India ‡ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92037, United States ABSTRACT: The hedgehog (Hh) pathway plays a central role in the development and repair of our bodies. Therefore, dysregulation of the Hh pathway is responsible for many developmental diseases and cancers. Basal cell carcinoma and medulloblastoma have well- established links to the Hh pathway, as well as many other cancers with Hh-dysregulated subtypes. A smoothened (SMO) receptor plays a central role in regulating the Hh signaling in the cells. However, the complexities of the receptor structural mechanism of action and other pathway members make it difficult to find Hh pathway inhibitors efficient in a wide range. Recent crystal structure of SMO with cholesterol indicates that it may be a natural ligand for SMO activation. Structural similarity of fluorinated corticosterone derivatives to cholesterol motivated us to study the effect of dexamethasone, fludrocortisone, and corticosterone on the Hh pathway activity. We identified an inhibitory effect of these three drugs on the Hh pathway using a functional assay in NIH3T3 glioma response element cells. Studies using BODIPY-cyclopamine and 20(S)-hydroxy cholesterol [20(S)-OHC] as competitors for the transmembrane (TM) and extracellular cysteine-rich domain (CRD) binding sites showed a non-competitive effect and suggested an alternative or allosteric binding site for the three drugs.
    [Show full text]